Spotted fever

Summary

Spotted fever (MONDO:0001195) is a disease (an umbrella term covering 11 Mondo subtypes). A subtype of Rickettsiaceae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 11 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	spotted fever
Mondo ID	MONDO:0001195
EFO	EFO:1002047
Orphanet	102022
DOID	DOID:11104
ICD-10-CM	A77
ICD-11	9953620
SNOMED CT	186771002
UMLS	C5680374
MedGen	1826170
GARD	0019828
Is cancer (heuristic)	no

Also known as: fever, spotted · fevers, spotted · spotted fever · spotted fever Group Rickettsioses · spotted fever Group rickettsiosis · spotted fever rickettsiae disease · spotted fever rickettsiosis · spotted fevers

Disease family

This is a subtype of Rickettsiaceae infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › Rickettsiosis › Rickettsiaceae infectious disease › spotted fever

Related subtypes (2): typhus, rickettsial pneumonia

Subtypes (11): African tick-bite fever, Flinders island spotted fever, Japanese spotted fever, Rickettsia parkeri spotted fever, Rickettsia helvetica spotted fever, Queensland tick typhus, Siberian tick typhus, Rickettsia conorii infectious disease, Rocky mountain spotted fever, rickettsialpox, pseudotyphus of California

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Azithromycin	Phase 3

Clinical trials & evidence

Clinical trials

Clinical trials: 0.